Form 4: Ligand Pharma CLO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Ligand Pharmaceuticals' Chief Legal Officer, Andrew Reardon, exercised stock options and subsequently sold a portion of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc., engaged in transactions on March 4, 2026.
- Reardon exercised 5,000 employee stock options at an exercise price of $52.27 per share.
- Concurrently, Reardon sold a total of 4,558 shares of common stock in multiple transactions.
- The sales occurred at weighted-average prices ranging from $197.6954 to $208.8724 per share.
- Following these transactions, Reardon directly owns 36,869 shares of common stock and 54,444 employee stock options.
- All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While insider sales can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns of opportunistic selling, and the exercise of options indicates the realization of vested compensation.
Positives
- Exercise of 5,000 employee stock options indicates the realization of vested compensation.
- The exercise price of $52.27 is significantly lower than the sale prices, indicating a substantial gain for the insider.
Negatives
- Sale of 4,558 shares of common stock by a key executive, which reduces direct ownership.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as a means for executives to manage personal finances and diversify holdings while adhering to insider trading regulations. These pre-arranged plans help mitigate concerns about opportunistic trading based on non-public information.
Stakeholder Impact
- Shareholders may observe a slight reduction in direct insider ownership, though the pre-arranged nature of the sales under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2023-02-01 | Initial vesting date for 12.5% of the employee stock option, with subsequent vesting in 42 substantially equal monthly installments. |
| 2025-11-24 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2026-03-04 | Date of reported stock option exercise and common stock sales transactions. |
| 2026-03-06 | Date the Form 4 was signed by Andrew Reardon. |
| 2032-08-01 | Expiration date of the employee stock option. |
Recommendation
holdThe transactions represent routine executive compensation management under a pre-established plan, rather than a signal of significant new information about the company's prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Ligand Pharmaceuticals, LGND, Andrew Reardon, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.